Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
作者信息
Xu Hai, Zhou Yong, Wu Huikun
机构信息
Department of Gynecology, HuangJiahu Hospital of Hubei University of Chinese Medicine, Hubei, China.
Department of Oncology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei, China.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e125-e127. doi: 10.3350/cmh.2024.1087. Epub 2024 Dec 17.
Abstract
摘要
相似文献
1
Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e125-e127. doi: 10.3350/cmh.2024.1087. Epub 2024 Dec 17.
2
Correspondence to letter to the editor 1 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e208-e209. doi: 10.3350/cmh.2024.1171. Epub 2025 Jan 6.
3
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e128-e133. doi: 10.3350/cmh.2024.1008. Epub 2024 Dec 26.
4
Correspondence to letter to the editor 2 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e210-e211. doi: 10.3350/cmh.2024.1175. Epub 2025 Jan 6.
5
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7.
6
Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study.
Dig Dis. 2025;43(1):36-45. doi: 10.1159/000541945. Epub 2024 Oct 14.
7
Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
J Hepatol. 2023 Dec;79(6):1374-1384. doi: 10.1016/j.jhep.2023.08.018. Epub 2023 Aug 28.
8
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
Liver Cancer. 2023 Dec 22;13(4):426-437. doi: 10.1159/000535943. eCollection 2024 Aug.
9
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study".
Clin Mol Hepatol. 2024 Oct;30(4):974-977. doi: 10.3350/cmh.2024.0417. Epub 2024 Jul 4.
10
Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
Int J Cancer. 2025 Jan 1;156(1):40-51. doi: 10.1002/ijc.35097. Epub 2024 Jul 17.
引用本文的文献
1
Correspondence to letter to the editor 1 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e208-e209. doi: 10.3350/cmh.2024.1171. Epub 2025 Jan 6.
本文引用的文献
1
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7.
2
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Front Med (Lausanne). 2021 Oct 8;8:734847. doi: 10.3389/fmed.2021.734847. eCollection 2021.
3
Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Am J Gastroenterol. 2018 Oct;113(10):1475-1483. doi: 10.1038/s41395-018-0041-8. Epub 2018 Mar 13.
4
Impact of the gut microbiota on inflammation, obesity, and metabolic disease.
Genome Med. 2016 Apr 20;8(1):42. doi: 10.1186/s13073-016-0303-2.
Zotero 插件